Identification of Allergen-reactive Antibodies in the Blood of Pollen Allergic Patients
Overview
The project examines the hypothesis that monoclonal allergen-neutralizing antibodies can be recombinantly produced from B lymphocytes isolated from pollen allergic patients. Patient samples suitable for antibody cloning are selected based on seroprofiling for the respective allergens. The study aims at isolating lymphocytes from patients with potential allergen-neutralizing IgG in serum and to clone antibodies from antibody gene sequences obtained from B cells of those patients.
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: September 30, 2024
Interventions
- Other: blood withdrawal
- Blood withdrawal
Clinical Trial Outcome Measures
Primary Measures
- Antibody profiling
- Time Frame: October 2018 – September 2021
- Analysis and IgG profiling of specific antibodies binding major grass- and tree-pollen allergens in allergic patients.
Participating in This Clinical Trial
Inclusion Criteria
- History of allergic rhinitis, conjunctivitis or asthma due to sensitization to grass- or birch Allergens – Male or female patients older than 18 years – Written informed consent for providing blood and also to allow experimental manipulation Exclusion Criteria:
- Age < 18 years – Any corticosteroids within the last three days – Oral corticosteroid therapy within the last ten days – Parenteral depot corticosteroids within the last three months
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
Investigator Details
- Lead Sponsor
- Mabylon AG
- Provider of Information About this Clinical Study
- Sponsor
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.